How Efforts In Gene Therapy Benefitted Rapid COVID-19 Vaccine Development
Source: Life Science Leader
In this executive virtual roundtable (EVR) component, Bryan Butman, Ph.D., head of CMC, Precigen, provides perspective on how early work in gene therapy benefitted the development of viral vector vaccines for COVID-19.
This website uses cookies to ensure you get the best experience on our website. Learn more